ClinicalTrials.gg
RecruitingNCT05446155BioMELUpdated Jan 23, 2024

BioMEL- Diagnostic and Prognostic Factors in Melanoma.

An observational study in Melanoma, Melanoma in Situ and Dysplastic Nevi, sponsored by Region Skane. Recruiting at 4 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-23.

Primary conditionDysplastic Nevus SyndromeRegistry: MelanomaReclassifiedWhy we changed it
Registry
Melanoma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Dysplastic Nevus Syndrome
Why
  1. The study's listed conditions name Dysplastic Nevus Syndrome, a narrower term within Melanoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Region Skane · Observational

How we know

From the registry’s dates

  • Started Nov 2013; still recruiting 13 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Study summary

The investigators' hypothesis is that cutaneous melanoma, melanoma in situ, dysplastic nevi and benign nevi all differ in not only clinical characteristics but also molecular and genotypic characteristics.

Patients with suspected primary cutaneous melanoma or a differential diagnosis, or secondary melanoma can be asked to participate in the first part of the project and patients with suspected or confirmed secondary (spread) melanoma can be included in the second part of the study. Participants included in the study answer a validated questionnaire regarding epidemiological and phenotypic factors to map medical history, prior UV exposure, family history of melanoma and/or other cancer types, skin type, smoking habits, alcohol use and quality of life.

Blood samples (whole blood) are collected before primary local excision and before secondary surgical procedures as well as during follow up of patients with secondary disease and oncologic treatment. During local excision of the primary pigmented skin lesion, full-thickness skin punch biopsies are taken by trained dermatologists. The biopsies, in the lesion and next to the lesion in the normal skin of the suspected melanoma, are taken, snap frozen and stored deep frozen. The primary lesions are documented by accurate imaging methods prior to excision.

Tissue samples from suspected or confirmed secondary melanomas are collected mainly through surgical and core needle biopsies before, during and after treatment and in case of disease progress or treatment failure. Tissue samples are snap-frozen and stored in the same way as samples from primary melanomas.

Comprehensive questionnaire based, imaging-based information, as well as histologic information provided from the pathologist report is included and stored in a secure database.

All the information in the database, along with information from molecular analysis of tissue and/or blood samples will then be used to find objective, molecular and clinical differences in melanoma, melanoma in situ, dysplastic and benign nevi along with potential information of biological aggressivity of both primary and secondary melanoma in order to find more objective diagnostic markers.

Read the detailed description

See above.

02

Conditions studied

  • Melanoma
  • Melanoma in Situ
  • Dysplastic Nevi
  • Mole (Dermatology)
  • Image
  • Mutation

Browse trials for

Keywords

  • Biobank
  • Melanoma
  • nevus
  • mole
  • dermoscopy
  • dermatoscopy
  • skin cancer
  • Sequence analysis, DNA
  • Sequence analysis, RNA
  • Whole genome sequencing
03

In context

Dysplastic Nevus Syndrome Reclassified

24 studies on the registry are indexed under Dysplastic Nevus Syndrome; 7 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 283 across 16 observational studies indexed under Dysplastic Nevus Syndrome.

Browse Dysplastic Nevus Syndrome studies →

Lead sponsor

Region Skane is the lead sponsor of 386 studies on the registry; 122 are open to participants now.

Compared within Dysplastic Nevus Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Melanoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult participants, clinical patients, recruited in the Southern Swedish health care region, Region Skane. Patients are recruited in the daily clinical practices in the departments of Dermatology, Surgery (including, ENT, Neuro, General surgery, Gynecology) and Oncology.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary part of the project: Patients in dermatological outpatient routine care in Helsingborg, Lund or Malmö Hospitals. Patients are planned for surgical excision for an equivocal pigmented skin lesion that could be a primary melanoma or a differential diagnosis of melanoma
  • Secondary part of the project: . Patient, in surgical or oncological routine care in Helsingborg, Lund, Malmö or Kristianstad Hospitals. Patients are planned for surgical excision or cytological diagnostics (needle aspiration) of melanoma.
  • All subjects have to be able to provide written .

Exclusion criteria

Exclusion Criteria:

  • Patients with lesions, primary or secondary, that are so small that a punch for the study would risk affecting the histopathological diagnosis.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients with a suspected primary melanoma or equivocal pigmented skin tumour

    Patients, 18 years or older, in dermatological outpatient routine care in Helsingborg, Lund or Malmö Hospitals. Patients are planned for surgical excision for an equivocal pigmented skin lesion that could be a primary melanoma or a differential diagnosis of melanoma. Imaging of tumours will be applied before surgery. Blood samples are taken before surgery. Tumour/normal skin biopsies will be taken and snap-frozen (-80°C) immediately after surgery. A baseline questionnaire about skin cancer risk factors, co-morbidities, phenotypic factors, diets, smoking, alcohol and quality of life will be given to the patient before surgery.

    Diagnostic Test: Imaging

  • Patients with secondary melanoma (metastatic disease)

    Patients, 18 years or older, in surgical or oncological routine care in Helsingborg, Lund, Malmö or Kristianstad Hospitals. Patients are planned for surgical excision or cytological diagnostics (needle aspiration) of metastatic melanoma. Imaging of tumours will be applied before surgery. Blood samples are taken before surgery. Tumour biopsies will be taken and snap-frozen (-80°C) immediately after surgery. A baseline questionnaire about skin cancer risk factors, co-morbidities, phenotypic factors, diets, smoking, alcohol and quality of life will be given to the patient before surgery.

    Diagnostic Test: Imaging

Interventions

  • Diagnostic testImaging

    Diagnostic and prognostic imaging, omics and machine learning methods will be applied

    Also known as: transcriptomics, genomics, metabolomics, histopathological examination, deep and spatial sequencing, dermoscopy, machine learning methods

06

What researchers measure

Primary outcomes

  1. Genomic and transcriptomic differences between cutaneous melanoma, melanoma in situ, dysplastic nevi and benign nevi.

    Genomic and transcriptomic differences as analysed from DNA and RNA collected from tumour tissue biopsies from cutaneous melanoma, melanoma in situ, dysplastic nevi and benign nevi.

    Time frame: Cross sectional (subjects included november 2013- december 2026.

  2. Interindividual genomic and transcriptomic differences in metastatic melanoma

    Genomic and transcriptomic differences as analysed from DNA and RNA collected from tumour tissue biopsies from metastatic melanoma.

    Time frame: Cross sectional (subjects included november 2013- december 2026.

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — For now, only researchers involved in the project can access the data, but this can change after completion of the data gathering.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2013 (actual). Primary completion is estimated for Dec 2026, 157 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2022
First posted
Jul 6, 2022
StartActual
Nov 4, 2013
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2028
Last update
Jan 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05446155
Lead sponsor
Region Skane
Responsible party
Sponsor
First posted
Jul 6, 2022
Start date
Nov 4, 2013
Primary completion
Dec 2026 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jan 23, 2024

Study contacts

Kari Nielsen, Ass. Prof.
Contact
kari.nielsen@med.lu.se
+46424061000
Kari Nielsen, Ass. Prof.
principal investigator · Lund University Cancer Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion